维拉普生(Vilaprisan)的临床药代动力学与药效学综述
维拉普生是治疗子宫肌瘤和子宫内膜异位症的高效选择性孕激素受体调节剂,口服吸收快、生物利用度近完全、暴露呈剂量比例。年龄、体重、种族不影响药代/药效,轻中度肾/肝损伤无需调整剂量,重度器官损伤不推荐使用。作为CYP3A4敏感底物,不建议与强CYP3A抑制剂或诱导剂合用,也不建议与含孕激素口服避孕药合用。
要点
- 维拉普生口服吸收快、生物利用度近完全、暴露与剂量成正比。
- 年龄、体重、种族不影响药代/药效,无需据此调整剂量。
- 轻中度肾/肝损伤无需调整剂量,重度器官损伤不推荐使用。
核心结论
- 维拉普生为高效选择性孕激素受体调节剂,口服吸收快、生物利用度近完全、暴露呈剂量比例。
- 年龄、体重、种族不影响维拉普生的药代/药效,无需剂量调整。
- 轻中度肾或肝损伤无需调整剂量,重度器官损伤不推荐使用。
- 维拉普生对CYP酶和转运体无抑制作用,但作为CYP3A4敏感底物,不建议与强CYP3A抑制剂或诱导剂合用。
- 维拉普生与强CYP3A抑制剂合用时无QTc延长风险,且不建议与含孕激素口服避孕药合用。
研究设计与样本
- 本文为维拉普生临床药代动力学与药效学的综合性综述。
主要发现
- 维拉普生口服吸收快、生物利用度近完全、暴露呈剂量比例。
- 年龄、体重、种族对维拉普生的药代/药效无临床相关影响。
- 轻中度肾或肝损伤无需调整剂量,重度器官损伤不推荐使用。
- 维拉普生对CYP酶和转运体无抑制作用,但作为CYP3A4敏感底物,与强CYP3A抑制剂或诱导剂合用受限。
- 维拉普生与强CYP3A抑制剂合用时无QTc延长风险。
关键数值与推荐
- 维拉普生暴露-效应关系陡峭,模拟显示2 mg/天预期可最大程度减少出血,已选为III期剂量。
临床怎么用
- 轻中度肾或肝损伤患者使用维拉普生无需调整剂量,重度器官损伤不推荐使用。
- 避免维拉普生与强CYP3A抑制剂或诱导剂合用。
- 避免维拉普生与含孕激素口服避孕药合用。
- 维拉普生与强CYP3A抑制剂合用时无需担心QTc延长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vilaprisan is a highly potent selective progesterone receptor modulator in development for the treatment of symptomatic uterine fibroids and endometriosis. Its pharmacokinetics are characterized by rapid absorption, almost complete bioavailability, and dose-proportional exposure. The intrinsic factors of age, bodyweight, and race have no clinically relevant effect on the pharmacokinetics and pharmacodynamics of vilaprisan and do not warrant a dose adjustment. Similarly, vilaprisan can be used in patients with mild or moderate renal or hepatic impairment without dose adjustment, but its use is not recommended in patients with severe organ impairment. Vilaprisan has no perpetrator potential on cytochrome P450 (CYP) enzymes or transporters and therefore restrictions in the concomitant use of their substrates are not required. Nonetheless, because it is a sensitive CYP3A4 substrate itself, concomitant use of vilaprisan with strong CYP3A inhibitors or inducers is not recommended. However, there is no risk for QTc prolongation when vilaprisan and a strong CYP3A inhibitor are administered concomitantly, as indicated by a vilaprisan concentration-QTc response analysis across all studies with triplicate electrocardiogram measurements. Furthermore, due to its mode of action, vilaprisan is also not recommended to be used together with progestin-containing oral contraceptives. Vilaprisan shows a steep exposure-response relationship for inducing amenorrhea in patients with uterine fibroids experiencing heavy menstrual bleeding. Based on simulations, a dose of 2 mg/day is expected to induce a maximum bleeding reduction and was thus selected for phase III.
引用
- Schultze-Mosgau MH, Ploeger BA, Frei M, et al. Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview. Clin Pharmacokinet. 2021. PMID: 34569009. doi:10.1007/s40262-021-01073-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。